This could have impacted the strength of the association between CYP2C19 LOF allele status and efficacy of clopidogrel therapy in preventing stroke recurrence, given that in a proportion of these patients antiplatelet therapy might not have been the best secondary prevention strategy. The gene discussed is CYP2C19; the disease is stroke disorder.